245,707 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Great Lakes Advisors LLC

Great Lakes Advisors LLC bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 245,707 shares of the company’s stock, valued at approximately $6,047,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Peak Retirement Planning Inc. bought a new stake in Elanco Animal Health in the 4th quarter worth approximately $2,756,000. Norges Bank purchased a new stake in Elanco Animal Health during the 4th quarter valued at $32,415,000. Geneos Wealth Management Inc. lifted its holdings in shares of Elanco Animal Health by 3,358.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 202,747 shares of the company’s stock valued at $4,852,000 after buying an additional 196,884 shares during the period. Allspring Global Investments Holdings LLC bought a new position in Elanco Animal Health in the first quarter valued at about $66,390,000. Finally, OP Asset Management Ltd purchased a new stake in shares of Elanco Animal Health during the 1st quarter valued at about $8,171,000. Institutional investors own 97.48% of the company’s stock.

Insider Activity

In other news, CFO Robert M. Vanhimbergen bought 4,200 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the purchase, the chief financial officer owned 137,516 shares in the company, valued at $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Paul Herendeen bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $23.68 per share, with a total value of $236,800.00. Following the acquisition, the director directly owned 111,687 shares in the company, valued at $2,644,748.16. This trade represents a 9.83% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 23,198 shares of company stock valued at $537,109. 1.14% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. JPMorgan Chase & Co. boosted their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. KeyCorp upped their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 31st. Finally, UBS Group lifted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Trading Up 3.5%

Shares of NYSE:ELAN opened at $24.47 on Thursday. The stock has a 50 day moving average of $24.57 and a 200 day moving average of $24.01. The company has a market cap of $12.22 billion, a PE ratio of -59.67, a price-to-earnings-growth ratio of 1.42 and a beta of 1.67. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same period in the prior year, the firm posted $0.26 EPS. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.